Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
BACKGROUND
The ongoing worldwide outbreak of the 2019-nCoV is markedly similar to the severe acute respiratory syndrome (SARS) outbreak 17 years ago. During the 2002-2003 SARS outbreak, healthcare workers formed a special population of patients. Although virus-specific IgG play important roles in virus neutralization and prevention against future infection, limited information is available regarding the long term persistence of IgG after infection with SARS-like coronavirus.
METHODS
A long-term prospective cohort study followed 34 SARS-CoV-infected healthcare workers from a hospital with clustered infected cases during the 2002-2003 SARS outbreak in Guangzhou, China, with a 13-year follow-up. Serum samples were collected annually from 2003-2015. Twenty SARS-CoV-infected and 40 non-infected healthcare workers were enrolled in 2015, and their serum samples were collected. All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS-CoV, as a diagnostic antigen.
RESULTS
Anti SARS-CoV IgG was found to persist for up to 12 years. IgG titers typically peaked in 2004, declining rapidly from 2004-2006, and then continued to decline at a slower rate. IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015. Patients treated with corticosteroids at the time of infection were found to have lower IgG titers than those without.
CONCLUSIONS
IgG antibodies against SARS-CoV can persist for at least 12 years. The presence of SARS-CoV IgG might provide protection against SARS-CoV and other betacoronavirus. This study provides valuable information regarding humoral immune responses against SARS-CoV and the 2019-nCoV.
Article activity feed
-
SciScore for 10.1101/2020.02.12.20021386: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The annual physical examination has been reviewed and supported by the hospital ethics review committee.
Consent: Written consent was signed at the first examination.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable The majority of the participants were aged between 20 and 30, in 2003, and 94.11% (32/34) of them were females (Table S1). Table 2: Resources
Antibodies Sentences Resources 2.3 DETECTION AND QUANTIFICATION OF IgG ANTIBODIES: Serum IgG antibodies were detected with a SARS-CoV IgG antibody enzyme-linked immunosorbent assay (ELISA) Kit (BGI-GBI Biotech Co. Ltd., Beijing, China), which used the whole … SciScore for 10.1101/2020.02.12.20021386: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The annual physical examination has been reviewed and supported by the hospital ethics review committee.
Consent: Written consent was signed at the first examination.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable The majority of the participants were aged between 20 and 30, in 2003, and 94.11% (32/34) of them were females (Table S1). Table 2: Resources
Antibodies Sentences Resources 2.3 DETECTION AND QUANTIFICATION OF IgG ANTIBODIES: Serum IgG antibodies were detected with a SARS-CoV IgG antibody enzyme-linked immunosorbent assay (ELISA) Kit (BGI-GBI Biotech Co. Ltd., Beijing, China), which used the whole SARS-CoV as the detection antigen. SARS-CoV IgGsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
